Abstracts from 2014 through the most recent CROI can be viewed in this searchable database once they have been presented at the conference. Abstract Contents: The searchable database includes abstract text as submitted by the authors prior to CROI. Study data might be updated during the presentation at CROI. Please refer to the electronic poster or webcast for updates. Searching the Abstract Database: Enter the criteria below and click the “Search” button. After the search has been entered, the results will appear below the search form.

CROI conference materials (eg, the conference program, Abstract eBook, electronic posters, CROI logo, etc) are protected by copyright. Permission to replicate or reproduce these elements, in whole or in part, must be obtained from the CROI Conference Manager, the International Antiviral Society-USA (IAS-USA). Study data (including figures within abstracts or electronic posters) are the property of the study authors. Permission to use data and figures cannot be given by IAS–USA unless it is for regulatory reasons. For more information, please email CROIabstracts@iasusa.org.

Search Results

1277 Results

686 – Implementation of LA-CAB/RPV in US Clinic Settings: A Survey of Front-Line Clinicians

Background Long-acting Cabotegravir and Rilpivirine (LA-CAB/RPV), approved in January 2021, is the first complete injectable regimen for virologically suppressed patients with HIV-1 without a history of resistance. The availability of LA-CAB/RPV offers a significant opportunity to expand the landscape of care for people with HIV. However, data on its implementation outside of early phase clinical…

687 – Distance to Care Measures Predict Injection Visit No-Shows Among Cabotegravir/Rilpivirine Recipients

Background Various distance to care (DTC) measures exist. It is unclear which most accurately predicts injection visit adherence for persons with HIV receiving long acting injectable (LAI) cabotegravir/rilpivirine (CAB/RPV). Objectives were to: i) identify which DTC measures were associated with injection visit no-shows (IVNS) and ii) compare the strength of association of each DTC measure…

689 – Long-Term Virologic Suppression Rates in the Ward 86 HIV Clinic’s Long-Acting ART Program (SPLASH)

Background The Ward 86 HIV Clinic in San Francisco serves publicly-insured people with HIV (PWH) living with multiple concomitant challenges. With the approval of long-acting (LA) cabotegravir/rilpivirine in 2021, Ward 86 started using LA antiretroviral therapy (ART) for those with adherence challenges to oral ART.  More than 3.5 years into the program, we now report…

726 – HIV-1 Env Exhibits Distinct Conformations and Neutralization Profiles in CSF and Blood

Background HIV-1 replicates in different body compartments and sub-compartments characterized by distinct compositions of small solutes and proteins. It is often assumed that virus proteins maintain the same conformation, function and sensitivity to inhibitors in different molecular environments, in vivo and in vitro. The protein albumin shows remarkable variability in concentration between the blood and…

755 – Cost-Effectiveness of Interventions to Reduce HCV Among People Who Inject Drugs in Haiphong, Vietnam

Background In Vietnam, including Haiphong, many hepatitis C virus (HCV) infections occur among people who inject drugs (PWID). In 2016, there were an estimated 10,000 people with a history of injecting drug use (IDU) in Haiphong. Multiple respondent-driven sampling (RDS) surveys tested for HCV among PWID in Haiphong, and a survey intervention (ANRS 12380 DRIVE-C)…

616 – Plasma Microbiome Composition Among Neurobehavioral Phenotypes (NBPs) in People With HIV (PWH)

Background Neurobehavioral disorders and gut dysbiosis continue to occur in treated PWH, but the relationship between the plasma microbiome and NBPs has not been investigated. Plasma microbiome analysis offers unique insights into systemic microbial translocation and immune responses. This study aimed to investigate the association between plasma microbiome composition and neurobehavioral phenotypes in PWH.  …

436 – Incidence and Predictors of STIs and Effect on Immune Activation in the HVTN 705/HPX2008 Trial

Background STIs are common among participants participating in HIV vaccine trials. STIs may lead to proliferated immune responses, which could affect immune responses induced by HIV vaccines.  Methods We conducted a secondary analysis of HVTN 705/HPX2008, a phase 2b placebo-controlled efficacy trial of Ad26.Mos4.HIV and aluminum phosphate-adjuvanted clade C gp140 in preventing HIV-1 infection in…

624 – No Evidence of a Detrimental Effect of Pitavastatin on Neurocognitive Function Among People With HIV

Background Equipoise exists regarding the effect of statins on cognitive function, with some observational studies suggesting harm and others suggesting benefit. Limited data among people with HIV (PWH) may be biased by indication for statin prescription.  Methods To assess statin effects on neurocognitive function among PWH, we leveraged data from participants co-enrolled in REPRIEVE (RCT…

458 – Natural Killer Cells Preferentially Kill HIV-Infected CD4 T Cells Using Death Receptors

Background Natural killer (NK) cells provide immune defense against virus infection via surveillance and recognition of virally infected cells. In people living with HIV (PWH) NK cell function has been associated with viral control and is being targeted for immunotherapeutic strategies. Methods To determine whether NK function is impaired in PWH, in vitro NK functional…

626 – Increased Cerebral Arterial Transit Time in Obese Females With HIV and Metabolic Syndrome

Background The prevalence of obesity, and subsequent metabolic syndrome (MetS), is increasing in persons living with HIV (PLWH) on antiretroviral therapy (ART), with nearly 1 in 4 meeting MetS criteria. African females with HIV are at particular risk of developing obesity complicated by MetS. Obesity increases the risk of cardiovascular and cerebrovascular disease. There is…